

August 15, 2018

CURRICULUM VITAE
Rishi R. Lulla, MD MS

Business Address: 593 Eddy Street, Multiphasic 117, Providence, Rhode Island 02903

Business Telephone Number: (401) 444-5171

Business Fax Number: (401) 444-8845

Electronic Mail Address: rishi_lulla@brown.edu

EDUCATION

Undergraduate Boston University, 1995-1999
Bachelor of Arts: Biology, Dean's List with Honors, magna cum laude,
awarded early admission to Medical Doctorate program

Medical School Boston University School of Medicine, 1999-2003

Other Degrees Northwestern University Feinberg School of Medicine, 2008-2010
Masters of Science in Clinical Investigation

POSTGRADUATE TRAINING

Residency Northwestern University Feinberg School of Medicine
240 E Huron St #1-200, Chicago, Illinois 60611
Pediatrics, 2003-2006
Chief Resident in Pediatrics, Children's Memorial Hospital 2006-2007

Fellowship Northwestern University Feinberg School of Medicine
240 E Huron St #1-200, Chicago, Illinois 60611
Pediatric Hematology, Oncology and Stem Cell Transplant, 2007-2010
Advanced Fellowship, Pediatric Neuro-Oncology, 2010-2011

POSTGRADUATE HONORS AND AWARDS

Resident Teacher of the Year, Children's Memorial Hospital Teaching Award, 2005

Fellow of the Year, Children's Memorial Hospital Teaching Award, 2008

Outstanding Faculty Teaching Award, Northwestern University Feinberg School of
Medicine Department of Pediatrics, 2013, 2014

Hero Award, for Outstanding Dedication and Contributions to Pediatric Neuro-Oncology,
Pediatric Brain Tumor Foundation, 2015

Chicago's Top Cancer Doctors, Chicago Magazine, 2017

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

Illinois State Physician License #036-114875 (C.S. 336076182), 2005

Board Certified in General Pediatrics, American Board of Pediatrics, 2006

Board Certified, Pediatric Hematology-Oncology, American Board of Pediatrics, 2011

Rhode Island State Medical License #16312, 2018

ACADEMIC APPOINTMENTS

Instructor, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 2006-2008

Assistant Professor, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 2011-2017

Associate Professor, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 2017-

HOSPITAL APPOINTMENTS

Attending Physician, General Academic Pediatrics, Children's Memorial Hospital, Chicago, Illinois, 2006-2007

Attending Physician, Emergency Medicine (Urgent Care), Children's Memorial Hospital, Chicago, Illinois, 2006-2011

Attending Physician, Hematology, Oncology, Neuro-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, 2011- 2018

Attending Physician, Pediatric Hematology-Oncology Central Dupage Hospital and Northwestern Medicine Proton Center, Warrenville, Illinois, 2012- 2018

Division Director, Pediatric Hematology-Oncology
Hasbro Children's Hospital/Rhode Island Hospital, Providence, Rhode Island 2018 -

OTHER APPOINTMENTS

Pediatric Brain Tumor Consortium
Biology Committee, 2012- 2018
Toxicity Monitoring Committee, 2014-2018
Data Safety Monitoring Board, 2018 -

Bear Necessities Pediatric Cancer Foundation
Scientific Advisory Board, 2013-

Children's Brain Tumor Tissue Consortium
Scientific Committee, 2013- 2018
Site Principal Investigator and Executive Committee, 2015- 2018
Executive Board Chair, 2016- 2018

Pacific Pediatric Neuro-Oncology Consortium
Site Principal Investigator, 2017- 2018

Ad Hoc Reviewer
Journal of Pediatric Hematology/Oncology 2012 -
Journal of Neuro-Oncology 2012 -
Child's Nervous System 2012 -
Cancer Genetics 2013 - 2016
Journal of Pediatric Neurosurgery 2013 -
Journal of Child Neurology 2013 -
PLOS One 2013 -
Neuro-Oncology 2015 -

HOSPITAL COMMITTEES

Pediatric Residency Program, Candidate Interviewer and Faculty Advisor, Ann & Robert H. Lurie Children's Hospital of Chicago 2011-

Division of Hematology, Oncology, Neuro-Oncology and Stem Cell Transplant
Educational Conferences and Morbidity and Mortality Conference, Ann & Robert H. Lurie Children's Hospital of Chicago, Physician Leader, 2012-

Provider Advisory Committee, Ann & Robert H. Lurie Children's Hospital of Chicago
Appointed Member, 2014-

Hematology-Oncology CLABSI Prevention Taskforce Ann & Robert H. Lurie Children's Hospital of Chicago, Member, 2016-

Institutional Review Board, Ann & Robert H. Lurie Children's Hospital of Chicago,
Appointed Member, 2016-

Ambulatory Leadership Steering Committee, Ann & Robert H. Lurie Children's Hospital of Chicago, Appointed Member, 2016-

Hematology, Oncology, Neuro-Oncology and Stem Cell Transplant Epic Beacon
Implementation Team, Ann & Robert H. Lurie Children's Hospital of Chicago Physician
Leader, 2017-

UNIVERSITY COMMITTEES

Lurie Cancer Center Scientific Review Committee, Northwestern University Feinberg School of Medicine, 2011-

Lurie Cancer Center Disease Team Charter, Co-Leader Pediatric Oncology, Northwestern University Feinberg School of Medicine, 2015-

MEMBERSHIP IN SOCIETIES

American Society of Pediatric Hematology Oncology, Member, 2007-

American Society of Clinical Oncology, Member, 2007-

Children's Oncology Group, Member, 2007-

Society of Neuro-Oncology, Member, 2009-

PUBLICATIONS LIST

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Patel D, Piotrowski ZH, **Lulla RR**. Multiple births among adolescent women in Illinois. *J Reprod Med*. 1997 Dec;42(12):779-84.
2. Kondo A, Goldman S, **Lulla RR**, Mania-Farnell B, Vanin EF, Sredini ST, Soares MB and Tomita T. Longitudinal assessment of regional directed delivery in a rodent malignant glioma model. *J Neurosurg Pediatr* 2009 Dec; 4(6):592-8.
3. **Lulla RR**, Thompson AT and Liem RI. Elevated soluble transferrin receptor levels reflect increased erythropoietic drive rather than iron deficiency anemia in pediatric sickle cell disease. *Pediatr Blood Cancer* 2010 Jul 15; 55(1):141-4.
4. **Lulla RR**, Allen GA, Zakarija A, and Green, D. Transplacental transfer of postpartum inhibitors to factor VIII. *Haemophilia* 2010 Jan; 16(1):14-7.
5. **Lulla RR**, Costa FF, Bischof JM, Chou PM, Bonaldo MF, Vanin EF, Soares, MB. Identification of Differentially Expressed microRNAs in Osteosarcoma. *Sarcoma* 2011 Article ID 732690, 6 pages.
6. Costa FF, Bischof JM, Vanin EF, **Lulla RR**, Wang M, Sredni ST, Rajaram V, Bonaldo MF, Wang D, Goldman S, Tomita T, Soares MB. (July, 2011). Identification of microRNAs as potential prognostic markers in ependymoma. *PLoS ONE* 6(10): e25114.
7. Rao VK, Haridas A, Nguyen TT, **Lulla RR**, Wainwright MS, Goldstein JL. Symptomatic Cerebral Vasospasm Following Resection of a Medulloblastoma in a Child. *Neurocrit Care*. 2013 Feb;18(1):84-8

8. Eckerdt F, Beauchamp E, Bell J, Iqbal A, Su B, Fukunaga R, **Lulla R**, Goldman S, Plataniias LC. Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells. Oncotarget. 2014 Sep 30;5(18):8442-51.
9. Merino DM, Shlien A, Villani A, Pienkowska M, Mack S, Ramaswamy V, Shih D, Tatevossian R, Novokmet A, Choufani S, Dvir R, Ben-Arush M, Harris BT, Hwang EI, **Lulla R**, Pfister SM, Achatz MI, Jabado N, Finlay JL, Weksberg R, Bouffet E, Hawkins C, Taylor MD, Tabori U, Ellison DW, Gilbertson RJ, Malkin D. Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups. Clin Cancer Res. 2015 Jan 1;21(1):184-92
10. Packer RJ, Rood BR, Turner DC, Stewart CF, Fisher M, Smith C, Young-Pouissant T, Goldman S, **Lulla R**, Banerjee A, Pollack I, Kun L, Onar-Thomas A, Wu S, Boyett JM, Fouladi M. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. J Neurooncol. 2015 Jan;121(1):217-24.
11. Brower JV, Gans S, Hartsell WF, Goldman S, Fangusaro JR, Patel N, **Lulla RR**, Smiley NP, Chang JH, Gondi V. Proton therapy and helical tomotherapy result in reduced dose deposition to the pancreas in the setting of cranio-spinal irradiation for medulloblastoma: implications for reduced risk of diabetes mellitus in long-term survivors. Acta Oncol. 2015 Apr;54(4):563-6
12. Malchenko S, Sredni ST, Hashimoto H, Kasai A, Nagayasu K, Xie J, Margaryan NV, Seiriki K, **Lulla RR**, Seftor RE, Pachman LM, Meltzer HY, Hendrix MJ, Soares MB. A mouse model of human primitive neuroectodermal tumors resulting from microenvironmentally-driven malignant transformation of orthotopically transplanted radial glial cells. PLoS One. 2015 Mar 31;10(3):e0121707
13. Torchia J, Picard D, Lafay-Cousin L, Hawkins CE, Kim SK, Letourneau L, Ra YS, Ho KC, Chan TS, Sin-Chan P, Dunham CP, Yip S, Ng HK, Lu JQ, Albrecht S, Pimentel J, Chan JA, Somers GR, Zielenska M, Faria CC, Roque L, Baskin B, Birks D, Foreman N, Strother D, Klekner A, Garami M, Hauser P, Hortobágyi T, Bognár L, Wilson B, Hukin J, Carret AS, Van Meter TE, Nakamura H, Toledano H, Fried I, Fults D, Wataya T, Fryer C, Eisenstat DD, Scheineman K, Johnston D, Michaud J, Zelcer S, Hammond R, Ramsay DA, Fleming AJ, **Lulla RR**, Fangusaro JR, Sirachainan N, Larbcharoensub N, Hongeng S, Barakzai MA, Montpetit A, Stephens D, Grundy RG, Schüller U, Nicolaidis T, Tihan T, Phillips J, Taylor MD, Rutka JT, Dirks P, Bader GD, Warmuth-Metz M, Rutkowski S, Pietsch T, Judkins AR, Jabado N, Bouffet E, Huang A. Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncol. 2015 May;16(5):569-82.
14. Aw-Zoretic J, Wadhvani NR, **Lulla RR**, Ryan ME. Imaging findings of anaplastic astrocytoma in a child with maple syrup urine disease: a case report. Childs Nerv Syst. 2015 Sep;31(9):1625-9

15. **Lulla RR**, Goldman S, Yamada T, Beattie CW, Bressler L, Pacini M, Pollack IF, Fisher PG, Packer RJ, Dunkel IJ, Dhall G, Wu S, Onar A, Boyett JM, Fouladi M. Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. Neuro Oncol. 2016 Mar 28
16. Iqbal A, Eckerdt F, Bell J, Nakano I, Giles FJ, Cheng SY, **Lulla RR**, Goldman S, Platanius LC. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110 α inhibition. Oncotarget 2016 Apr 21.
17. Hashizume R, Zhang A, Mueller S, Prados MD, **Lulla RR**, Goldman S, Saratsis AM, Mazar AP, Stegh AH, Cheng SY, Horbinski C, Haas-Kogan DA, Sarkaria JN, Waldman T, James CD. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro-Oncol. 2016 Jul 1
18. Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, Norman JD, Guilhamon P, Garzia L, ... **Lulla RR**, ... Pietsch T, Judkins AR, Hawkins CE, Bouffet E, Kim SK, Dirks PB, Taylor MD, Erdreich-Epstein A, Arrowsmith CH, De Carvalho DD, Rutka JT, Jabado N, Huang A. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell. 2016 Dec 12.
19. Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendelman EJ, Ma Q, Takahashi YH, Woodfin AR, Misharin AV, Abshiru NA, **Lulla RR**, Saratsis AM, Kellerher NL, James CJ, Shilatifard A. Heterotypic nucleosomes and PRC2 drive DIPG oncogenesis. Nature Medicine 2017 Apr 23.
20. Huang TY, Piunti A, **Lulla RR**, Qi J, Horbinski CM, Tomita T, James CD, Shilatifard A, Saratsis AM. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun. 2017 Apr 17.
21. Finelt N, **Lulla RR**, Melin-Aldana H, Ruth JS, Lin FY, Su JM, Pourciau CY, Hunt RD, Kenner-Bell BM. Bumps in the Road: Panniculitis in Children and Adolescents Treated with Vemurafenib. Pediatr Dermatol. 2017 May.
22. Marini BL, Benitez LL, Zureick AH, Salloum R, Gauthier AC, Brown J, Wu YM, Robinson DR, Kumar C, Lonigro R, Vats P, Cao X, Kasaian K, Anderson B, Mullan B, Chandler B, Linzey JR, Camelo-Piragua SI, Venneti S, McKeever PE, McFadden KA, Lieberman AP, Brown N, Shao L, Leonard MAS, Junck L, McKean E, Maher CO, Garton HJL, Muraszko KM, Hervey-Jumper S, Mulcahy-Levy JM, Green A, Hoffman LM, Dorris K, Vitanza NA, Wang J, Schwartz J, **Lulla R**, Smiley NP, Bornhorst M, Haas-Kogan DA, Robertson PL, Chinnaiyan AM, Mody R, Koschmann C. Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. Transl Res. 2017 Oct.

23. Choi DK, Pillay-Smiley N, Marzec S, Wadhvani NR, DiPatri AJ, Tomita T, **Lulla RR**. Primary Central Nervous System Malignant Melanoma in Children: A Case Series and Review of the Literature. *J Pediatr Hematol Oncol*. 2018 Feb 2. doi: 10.109
24. Shaik S, Kennis B, Maegawa S, Schadler K, Yanwen Y, Callegari K, **Lulla RR**, Goldman S, Nazarian J, Rajaram V, Fangusaro J, Gopalakrishnan V. REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. *Oncotarget*. 2017 Dec 28;9(4):5233-5250. doi: 10.18632/oncotarget.23750. eCollection 2018 Jan 12.

OTHER PEER-REVIEWED PUBLICATIONS

1. **Lulla RR**, Foy AB, DiPatri AJ and Fangusaro J. Emergencies in children and young adults with central nervous system tumors. *Clinical Pediatric Emergency Medicine* September 2011.
2. **Lulla RR**, Saratsis AM, Hashizume R. Mutations in chromatin machinery and pediatric high-grade glioma. *Sci Adv*. 2016 Mar 18;2(3): e1501354.
3. Ladomersky E, Gene M, Zhai L, Galina G, Lauing KL, **Lulla RR**, Fangusaro J, Lenzen A, Kumthekar PK, Raizer JJ, Binder DC, James CD, Wainwright DA. Improving Vaccine Efficacy Against Malignant Glioma. *Oncoimmunology* . 2016 Jun 10

BOOKS AND BOOK CHAPTERS

1. **Lulla RR** and Fangusaro J. “An overview of pediatric high-grade gliomas and diffuse intrinsic pontine glioma.” in *Tumors of the Central Nervous System*. Springer Publishing 2013
2. Sredni ST and **Lulla RR**. “Atypical teratoid rhabdoid tumors.” in *Tumors of the Central Nervous System* Springer Publishing 2013

ABSTRACTS

1. **Lulla RR**, Costa FF, Hamm CA, Fangusaro J, Sredni ST, Vanin EF, Goldman S, Soares MB. Circulating microRNAs in plasma and cerebrospinal fluid of pediatric patients with central nervous system tumors. Society of Neuro-Oncology Pediatric Translational Meeting, New Orleans, May 2011.
2. **Lulla RR**, Echevarria M, Alden T, DiPatri AJ Tomita, T, Goldman S and Fangusaro J. “Primary Thalamic Tumors of Astrocytic Origin: A 20-year Experience at Children's Memorial Hospital.” *Neuro Oncol* (2012) 14 (suppl 1): i56-i68.
3. Fernandez KS, Antony R, **Lulla RR**, Flores M, Benavides VC, Mitchell C. Brainstem Glioma Responsive to Pegvisomant and Chemotherapy in a Patient with NF-1 Related Optic Pathway Glioma and Growth Hormone Excess. *Neuro Oncol* (2012) 14 (suppl 1): i69-i81.
4. Rubens J, **Lulla RR**, Lai JS, Fangusaro J. A Pilot Study Evaluation Long-Term Impact of Posterior Fossa Syndrome on Quality of Life in Survivors of Childhood Medulloblastoma. *Neuro Oncol* (2012) 14 (suppl 1): i111-i115.

5. Goldman S, Fangusaro J, **Lulla RR**, Chi S, Manley P, Robison N, Kroon HA, Kieran M. “Phase I Individual Dose Titration Trial of the Human Corticotrophin Releasing Factor (HCRF), Corticorelin Acetate Injection (Xerecept) in Pediatric Patients with Peritumoral Edema of the Brain” Neuro Oncol (2012) 14 (suppl 1): i16-i21.
6. Loret De Mola R, Laskowski J, Fangusaro J, Costa FF, Vanin EF, Goldman S, Soares MB, **Lulla RR**. Clinical and Biological Characteristics of Clear Cell Ependymoma. Neuro Oncol (2013) 15 (suppl 1): i1-i51.
7. **Lulla RR**, Rao VK, Haridas A, Ryan M, Goldstein JL, Wainwright MS, Tomita T. Symptomatic Cerebral Vasospasm Following Resection of Childhood Medulloblastoma. Neuro Oncol (2012) 14 (suppl 1): i116-i120.
8. Datar V, Bocharé S, Singh A, Khatua S, Fangusaro J, Goldman S, **Lulla RR**, Rajaram V, Gopalakrishnan V. Study of Histone Methyl Transferase G9a Inhibition in ATRT and Medulloblastoma. Neuro Oncol (2013) 15 (suppl 1): i1-i51.
9. **Lulla RR**, Laskowski J, Fangusaro J, DiPatri AJ, Alden T, Vanin EF, Tomita T, Goldman S, Soares MB. Longitudinal assessment of circulating microRNAs biomarkers in pediatric central nervous system tumors. Neuro Oncol (2013) 15 (suppl 1): i1-i51.
10. **Lulla RR**, Laskowski J, Gireud M, Fangusaro J, Goldman S, Gopalakrishnan V. Expression of miR-203 is associated with an aggressive phenotype in pediatric medulloblastoma. Neuro Oncol (2013) 15 (suppl 1): i1-i51.
11. Kumthekar P, Singh S, Pillay Smiley N, **Lulla RR**. Widespread Systemic Metastases from Medulloblastoma Without Evidence of Active CNS Involvement: A Case Series. Neuro Oncol (2014) 16(suppl 5): v68.
12. **Lulla RR**, Laskowski J, Goldman S, Gopalakrishnan V, Fangusaro J. MicroRNA Profiling Reveals Two Subgroups of Diffuse Intrinsic Pontine Glioma. Neuro Oncol (2014) 16(suppl 1): i40-i59.
13. **Lulla RR**, Goldman S, Beattie C Pollack IF, Fisher PG, Boyett JM, Fouladi M. Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors: A Pediatric Brain Tumor Consortium Study. Neuro Oncol (2014) 16(suppl 1):i10-i13.
14. Dobson T, Busschers E, Taylor H, Hatcher R, Fangusaro J, **Lulla RR**, Goldman S, Rajaram V, Das C, Gopalakrishnan V. Generation of a Novel Genetic Engineered Mouse Model of Medulloblastoma. Neuro Oncol (2014) 16(suppl 1):i137-i145.
15. Goldman S, Fangusaro J, **Lulla RR**, Chi S, Manley P, Robison N, Kroon HA, Kieran M. Phase I Individual Dose Titration Trial of the Human Corticotrophin Releaseing Factor (HCRF), Corticorelin Acetate Injection (Xerecept) in Pediatric Patients with Peritumoral Edema of the Brain. Neuro Oncol (2014) 16 (suppl 3):iii23
16. **Lulla RR**, Laskowski J, Fangusaro J, DiPatri AJ, Alden T, Vanin EF, Tomita T, Goldman S, Soares MB. Longitudinal assessment of circulating microRNAs identified promising biomarkers in pediatric central nervous system tumors. Neuro Oncol (2014) 16(suppl 1):i137-i145.
17. **Lulla RR**, Laskowski J, Bi Y, Pillay Smiley N, Fangusaro J, Goldman S, Gopalakrishnan V. MicroRNA Expression Patterns in Tissue and Cerebrospinal Fluid Aid in the Molecular Classification of Pediatric Medulloblastoma. Neuro-Oncol (2015) 17(suppl 3):iii26-iii27.
18. **Lulla RR**, Goldman S, Yamada T, Beattie CW, Bressler L, Pacini M, Pollack IF, Fisher PG, Packer RJ, Dunkel IJ, Dhall G, Wu S, Onar A, Boyett JM, Fouladi M. Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric

- patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. J Clin Oncol 33, 2015 (suppl; abstr 10059).
19. Dobson T, Tao RH, Shavali D, Taylor P, Hatcher R, Buscchers E, Khatua S, Goldman S, **Lulla RR**, Rajaram V, MacDonald T, Fangusaro J, Gopalakrishnan V. Dissecting the role of Epigenetic Modulators in Shh-Drive Medulloblastoma” Neuro Oncol (2015) 17 (suppl3): iii26.
 20. Hatcher R, Das C, Fangusaro J, Rajaram V, **Lulla RR**, Goldman S, Khatua S, Sbardella G, Gopalakrishnan V. Study of Epigenetic Dysregulation of a Novel Deubiquitylase in Medulloblastoma. Neuro Oncol (2015) 17 (suppl 3): iii8.
 21. Ma Q, Mu L, Saratsis A, **Lulla RR**, Fangusaro J, Goldman S, James CD, Hashizume R. Histone Demethylase Inhibition in Combination with Radiation for Diffuse Intrinsic Pontine Gliomas. Neuro Oncol (2015) 17(suppl 5):v180-v181.
 22. Qi J, Wadhvani N, Xi G, **Lulla RR**, Hashizume R, Tomita T, James CD, Saratsis A. In Vitro analysis of Tenascin-C Expression in Pediatric Brainstem Glioma. Oral Presentation: 84th Annual Meeting of the American Association of Neurological Surgeons, Chicago, IL May 2, 2016.
 23. Lauing KL, **Lulla RR**, Hashizume R, Wainwright DA. Immunosuppressive IDO1 and TDO are expressed in pediatric central nervous system tumors. International Society of Pediatric Neuro-Oncology, Liverpool, England, June 2016
 24. Clymer JR, Eckerdt F, Bell, JB, **Lulla RR**, Goldman S, Platanius LC. Dual targeting of PI3K and mTOR signaling in medulloblastoma. International Society of Pediatric Neuro-Oncology, Liverpool, England, June 2016
 25. Lauing KL, **Lulla RR**, Hashizume R, Wainwright DA. “Characterizing IDO1 and its therapeutic potential in human pediatric brain cancer”. Society of Neuro-Oncology, Pediatric Meeting, New York City June 2017
 26. Felmeister A, **Lulla RR**, Waanders AJ, Raman P, Santi M, Lily J, Mason J, Resnick AC on behalf of the Children’s Brain Tumor Tissue Consortium. “The Children’s Brain Tumor Tissue Consortium (CBTTC) Infrastructure Facilitates Collaborative Research in Pediatric Central Nervous System Tumors” Society of Neuro-Oncology, Pediatric Meeting, New York City June 2017
 27. Pratt D, Nataraj S, Banda A, Quezado M, Vats P, Koschmann C, Mody R, Chinnaiyan R, **Lulla RR**, Saratsis A, Venneti, S. “ A Meta-Analysis of H3K27M Mutations in Gliomas Demonstrates Differential Location-Dependent Prognostic Outcomes” United States and Canadian Academy of Pathology Meeting Vancouver, Canada March 2018.
 28. Saratsis A, Piunti A, Huang A, Bartom E, Ozark P, Marshall S, Morgan M, Qi J, Hashizume R, **Lulla RR**, James CD, Shilatifard A. “Diffuse Intrinsic Pontine Glioma (DIPG) Sequencing Reveals Epigenetic Dysregulation of Gene Expression and BET Inhibition as a Novel Therapeutic Strategy” AANS Meeting, New Orleans, April 2018.

INVITED PRESENTATIONS

Local

1. “Pediatric Brain Tumors: Updates in Treatment and Care” American Brain Tumor Association Patient and Family Conference, July 2011 and July 2012

2. “Linking Molecular Biology to Novel Treatments in Pediatric Central Nervous System Tumors” Ann & Robert H. Lurie Children’s Hospital of Chicago, Pediatric Grand Rounds, Chicago, Illinois October 2012.
3. “Pediatric Central Nervous System Tumors: Updates in Treatment and Care” Northwestern University Affiliated Transplant Centers Meeting, Chicago, Illinois June 2012
4. “Linking Molecular Biology to Novel Treatments in Pediatric Central Nervous System Tumors” Department of Neurological Surgery, Grand Rounds, Northwestern University Feinberg School of Medicine, Chicago, Illinois January 2014.
5. “Case Studies and Deliberation in the Pediatric Oncology Clinic” Oncofertility Conference, Northwestern University, September 2014.
6. “Contemporary Management of Adults with Pediatric Central Nervous System Tumors” Northwestern Brain Tumor Institute Symposium, Chicago, Illinois, March 2015.
7. “Linking Molecular Biology to Novel Treatments in Pediatric Central Nervous System Tumors” Combined Department of Pediatric Grand Rounds, Rush University School of Medicine and Cook County Hospital, Chicago, Illinois, December 2015.
8. “Linking Molecular Biology to Novel Treatments in Pediatric Central Nervous System Tumors” Lurie Cancer Center Grand Rounds, Northwestern University Feinberg School of Medicine, January 2016
9. “Next Generation Sequencing Informs Treatment in Pediatric Central Nervous System Tumors: Implications for Research and Clinical Care” Pediatric Brain Tumor Foundation Meet the Experts Conference, August 2016

Regional, National and International

1. “Targeted Therapies for Pediatric Central Nervous System Tumors” Southern Illinois University, Pediatric Grand Rounds, Springfield, Illinois. September 2011.
2. “MicroRNAs as Biomarkers in Pediatric Central Nervous System Tumors”, World Biotechnology Conference, Boston, Massachusetts, June 2013.
3. “Linking Molecular Biology to Novel Treatments in Pediatric Central Nervous System Tumors” Department of Pediatric Grand Rounds, University of Texas MD Anderson Cancer Center, May 2014.
4. “Common Adverse Events in Patients with Central Nervous System Tumors: A Coding Primer” Pediatric Brain Tumor Consortium Annual Meeting, Atlanta Georgia, March 2015.
5. “MicroRNAs as Biomarkers in Pediatric Central Nervous System Tumors” Children’s Brain Tumor Tissue Consortium Meeting, Philadelphia, Pennsylvania, April 2015.
6. “Immunosuppressive IDO1 and TDO in pediatric central nervous system tumors” Children’s Brain Tumor Tissue Consortium, New Orleans, Louisiana, May 2016.
7. “Immunosuppressive IDO1 and TDO in pediatric central nervous system tumors” Children’s Brain Tumor Tissue Consortium, Washington DC, May 2017.
8. “Lenalidomide and Radiation Therapy for Children with Malignant Glioma” Gliomatosis Cerebri International Conference, Bethesda Maryland, June 2017
9. “Precision Medicine Studies for Pediatric Central Nervous System Tumors” Barrow Neurological Institute at Phoenix Children's Hospital, November 2017.

10. “Precision Medicine Studies for Pediatric Central Nervous System Tumors” Hudson Institute of Medical Research Pediatric CNS Cancer Research Symposium, Melbourne Australia, Invited February 2018

GRANTS

Fellowship Training Awards

1. Coleman Foundation Fellowship in Hematology, Oncology and Stem Cell Transplant, 2007-2010
2. Gus Foundation Fellowship in Pediatric Neuro-Oncology, 2010-2011

Foundation Research Grants

1. A Feasibility Study of Circulating microRNAs as Disease Markers in Pediatric Cancers Hyundai Hope on Wheels Research Grant (\$20,000), Principal Investigator, 2011
2. Longitudinal profiling of microRNA expression in patients with CNS tumors St. Baldrick’s Foundation Research Grant (\$100,000), Principal Investigator, 2012
3. Longitudinal profiling of microRNA expression in patients with CNS tumors Bear Necessities and Flashes of Hope (\$80,000), Principal Investigator, 2012
4. Children’s Brain Tumor Tissue Consortium (CBTTC) Registry and Repository Children’s Brain Tumor Foundation (\$75,000/year), Co-Investigator (PI: Goldman), 2014
5. RNAi-based spherical nucleic acid and nanoconjugates for the treatment of pediatric high-grade glioma, John McNicholas Pediatric Brain Tumor Foundation (\$200,000), Co-Principal Investigator, 2015
6. Children’s Brain Tumor Tissue Consortium (CBTTC) Registry and Repository (\$90,000/year), Principal Investigator, 2015-
7. Modifying the Future: Epigenetic Treatment of Pediatric Brain and Spinal Cord Tumors John McNicholas Pediatric Brain Tumor Foundation (\$1,500,000/3 years), Principal Investigator, 2016-
8. Epigenetic Targeted Therapy for Pediatric Malignant Glioma, Pediatric Cancer Research Foundation (\$100,000/ 2 years), Co-Principal Investigator, 2017
9. IDO1 as a Therapeutic Target for Pediatric Malignant Glioma, Curing Kids Cancer Foundation (\$50,000), Co-Principal Investigator, 2017

Government Sponsored Clinical Trial Research

2011 – Pediatric Brain Tumor Consortium U01CA81457, Site Co-Investigator (Site Principal Investigator: Goldman)

1. PBTC-026: A Feasibility Study of SAHA combined with Isotretinoin and Chemotherapy in Infants with Embryonal Tumors of the Central Nervous System, Co-Investigator
2. PBTC-027: A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors, Co-Investigator
3. PBTC-029: A Phase I and Phase II Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma, Co-Investigator
4. PBTC-030: A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas, Co-Investigator
5. PBTC-031: Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients with Refractory or Recurrent CNS Tumors, Co-Investigator
6. PBTC-036: A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children with Recurrent High-Grade Glioma, Ependymoma, Medulloblastoma/Primitive Neuroectodermal Tumor and Diffuse Intrinsic Pontine Glioma, Co-Investigator
7. PBTC-041: A Phase I Trial of p28 (NSC745104), a Non-HDM2 mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors, Co-Principal Investigator
8. PBTC-029B: A Phase I and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma, Co-Investigator
9. PBTC-033: A Phase I/ II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas (DIPG), Co-Investigator
10. PBTC-039: Phase II study of Peginterferon alfa-2b (PEGIntron) for pediatric patients with unresectable or recurrent craniopharyngioma, Co-Investigator
11. PBTC-042: A Phase I Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors, Co-Investigator
12. PBTC-043: A Phase I Trial of Pomalidomide for children with recurrent, progressive or refractory CNS tumors, Co-Investigator
13. PBTC-045: A Safety and Preliminary Efficacy trial of MK-3475 (pembrolizumab; anti-PD-1) in Children with recurrent, progressive or refractory high-grade gliomas (HGG) and DIPGs, Co-Investigator
14. PBTC-047: A Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma, Co-Investigator
15. PBTC-048: Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma , Co-Investigator

1. ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial, Co-Investigator
2. ACNS0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients, Co-Investigator
3. ACNS0334: A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate, Co-Investigator
4. ACNS0821: Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial, Co-Investigator
5. ACNS0822: A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab (IND # 7921) and Temozolomide in Newly Diagnosed High Grade Glioma, Co-Investigator
6. ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years, Co-Investigator
7. ACNS0927: A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, followed by Maintenance SAHA in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG), Co-Investigator
8. ACNS1021: A Phase II Study of Sunitinib (NSC# 736511, IND# 74019) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Brain Tumors in Pediatric and Young Adult Patients, Co-Investigator
9. ACNS1022: A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas, Co-Investigator
10. ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT), Co-Investigator
11. ACNS1221: A Phase II Study for The Treatment of Non-Metastatic Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age, Co-Investigator
12. ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients, Co-Investigator

2011 –

Children's Oncology Group Phase I Consortium, UM1CA097452 Site Co-Investigator (Site Principal Investigator: Goldman)

1. ADVL0919: A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children with Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-cell Leukemia, Co-Investigator
2. ADVL1013: A Phase 1 Study of MK-2206, an AKT inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors or Leukemia, Co-Investigator
3. ADVL1111: A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND#112603) in Children with Relapsed or Refractory Solid Tumors, Co-Investigator
4. ADVL1112: A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children with Refractory or Recurrent Solid Tumors and Lymphoma, Co-Investigator
5. ADVL1211: A Phase 1 study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents with Recurrent or Refractory Solid Tumors, including CNS Tumors, Co-Investigator
6. ADVL1217: A Phase 1 Study of AZD1775 (MK-1775, IND#116459) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas, Co-Investigator
7. ADVL1312: A Phase 1/2 Study of AZD1775 (MK-1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors, Co-Investigator
8. ADVL1411: A Phase 1/2 Study of BMN 673 (IND #121510), an Oral Poly(ADP-ribose) Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies, Co-Investigator
9. ADVL1414: A Phase 1 Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors, Co-Investigator
10. A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma, Co-Investigator
11. ADVL1515: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors, Co-Investigator
12. ADVL1514: A Phase 1 Study of ABI-009 (nab-rapamycin) in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan, Co-Investigator

2014

A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults with NF1- Associated Morbid Plexiform Neurofibromas

Sponsor: Department of Defense, USAMRMC, Office of the Congressionally Directed Medical Research Programs (CDMRP), Site Co-Investigator, Site Principal Investigator: Goldman

2015 A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects with Neurofibromatosis Type 1 age 16 years or greater

Sponsor: Department of Defense, USAMRMC, Office of the Congressionally Directed Medical Research Programs (CDMRP), Site Co-Investigator, Site Principal Investigator: Goldman

Industry Sponsored Clinical Trial Research

2012 A Phase I Study of AdV-tk + Prodrug Therapy in Combination with Radiation Therapy for Pediatric Brain Tumors

Sponsor: Advantagene, Inc., Site Co-Investigator, Site Principal Investigator: Goldman

2013 A Phase III, multi-center, open label, randomized controlled study of the efficacy and safety of oral LDE225 versus temozolomide in patients with Hh-pathway activated relapsed medulloblastoma

Sponsor: Novartis, Inc., Site Co-Investigator, Site Principal Investigator: Goldman

2013 A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab Children with Solid Tumors

Sponsor: Amgen Inc., Site Co-Investigator, Site Principal Investigator: Fangusaro

2014 Open-label, phase 2 study of bevacizumab in children and young adults with neurofibromatosis 2 and progressive vestibular schwannomas that are poor candidates for standard treatment with surgery or radiation

Sponsor: USMRMC, Office of the Congressionally Directed Medical Research Programs (CDMRP), Department of Defense (DOD) and Genentech, Site Co-Investigator, Site Principal Investigator: Goldman

2014 Ted12689: A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients with Refractory Solid Tumors including Tumors of the Central Nervous System

Sponsor: Sanofi Inc., Site Co-Investigator, Site Principal Investigator: Goldman

- 2016 - A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
- Sponsor: Merck & Co, Site Co-Investigator, Site Principal Investigator: Goldman
- 2016 – Pacific Pediatric Neuro-Oncology Consortium, Site Co-Principal Investigator
1. PNOC001: Phase II Study of everolimus for recurrent or progressive low-grade gliomas in children
Sponsor: Novartis, Site Principal Investigator
 2. PNOC-002: Safety, Phase 0, and Pilot Efficacy Study of vemurafenib, an oral inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors
Sponsor: Genentech, Site Principal Investigator
 3. PNOC-003: A pilot trial testing the clinical benefit of using molecular profiling to determine an individualized treatment plan in children and young adults with newly diagnosed DIPG.
Sponsor: PNOC, Site Principal Investigator
 4. PNOC 005: A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT)
Sponsor: PNOC, Site Principal Investigator
 5. PNOC-007: H3.3K27M Specific Peptide Vaccine Combined with poly-ICLC for the Treatment of newly diagnosed HLA-A2+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) as well as other newly diagnosed HLA-A2+ H3.3K27M Positive Gliomas
Sponsor: PNOC, Site Principal Investigator
- 2016 – A Phase I and Feasibility Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Pediatric Patients with Newly Diagnosed Intracranial Resectable High Grade Glioma (Arm A) and Recurrent Resectable Intracranial High Grade Glioma and Recurrent Resectable Ependymoma (Arm B)
- Sponsor: Agenus Inc., Site Co-Investigator, Principal Investigator: Fangusaro
- 2017 – Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies
- CheckMate908: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 908

Sponsor: Bristol-Myers Squibb, Co-Investigator, Principal Investigator: Goldman

2017 – A Phase 2 Clinical Study of Pomalidomide (CC-4047) Monotherapy For Children and Young Adults with Recurrent or Progressive Primary Brain Tumors

Sponsor: Celgene Corporation., Site Co-Investigator, Principal Investigator: Fangusaro

2017 – A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects

Sponsor: Ziopharm Oncology, Site Co-Investigator, Principal Investigator: Goldman

2017 – NEXT17C03: Newly Diagnosed Children (Less Than 10 Years Old) with Medulloblastoma and Other Central Nervous System Embryonal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Either Single Cycle (Low Risk Patients) or Randomization (High Risk Patients) to Either Single-Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue (Head Start IV)

Sponsor: NEXT Consortium, Site Co-Investigator, Principal Investigator: Pillay-Smilely

2017 – Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive relapsed or refractory High Grade Glioma (HGG)

Sponsor: Novartis, Site Co-Investigator, Principal Investigator: Goldman

Forthcoming Studies

1. ACNS1723: A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG), Children's Oncology Group, Study Principal Investigator
2. A Phase I Trial of BPM 31510 Monotherapy in Children with Recurrent, Progressive or Refractory Solid or Central Nervous System Tumors, Study Principal Investigator

UNIVERSITY TEACHING, ADVISING and MENTORING ROLES

Didactic Teaching

Science in Medicine: Pediatric Cancer, 2013-2018

Annual lecture for Northwestern University Feinberg School of Medicine M2 students

HOSPITAL TEACHING, ADVISING and MENTORING ROLES

Didactic Teaching

Morning Report and Strategies for Leading Case-Based Resident Education

Annual lecture and discussion for chief pediatric residents, 2008-2018

Central Nervous System Tumors in Children and Adolescents, 2011-2018

2 lectures annually for Pediatric Resident Noon Conference Series

Topics in Biology of Pediatric Brain and Spinal Cord Tumors and Management of Children and Adolescents with Central Nervous System Tumors, 2011-2018

4 lectures annually for Pediatric Hematology-Oncology Fellow Lecture Series

Topics in Biology of Pediatric Brain and Spinal Cord Tumors and Management of Children and Adolescents with Central Nervous System Tumors, 2011-2018

12-15 lectures annually for Pediatric Neuro-Oncology Fellowship Lecture series

Clinical Teaching

Bedside teaching of medical students, residents, nurse practitioners and fellows during inpatient service weeks and 96 ambulatory clinic sessions per year

Case based teaching at pediatric resident morning report 18-20 times per year

Mentees

2011 –2013 Jeffrey Rubens MD, Resident Research Mentor

2012 –2015 Dustin Dillon MD, Resident Research Mentor

2012 –2013 Rebecca Loret De Mola DO, Neuro-Oncology Fellowship Research Mentor

2013 –2014 Natasha Pillay Smiley DO, Neuro-Oncology Fellowship Research Mentor

2014 –2015 Maggie Skrypek MD, Neuro-Oncology Fellowship Research Mentor

2015 –2017 Jessica Clymer MD, Hematology-Oncology Fellowship Research Mentor

2016 – Alicia Lenzen MD, Hematology-Oncology Fellowship Research Mentor

2017 – Kathryn Laurie, MD, Hematology-Oncology Fellowship Research Mentor